Company: AGIO
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001439222-25-000116
Chunk: 108

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part II, Item 1A
Chunk 108
---
 predict, such impacts have already caused, and are likely to result in further, significant disruption of global financial markets, which may reduce our ability to access capital either at all or on favorable terms.  

The market price for our common stock may be influenced by many factors, including: 

•our success in launching and commercializing PYRUKYND®;  

•announcements by us or our competitors of significant acquisitions, in-licensing arrangements, strategic partnerships, joint ventures, collaborations or capital commitments; 

•the timing and results of clinical trials of product candidates, or our competitors’ product candidates; 

•regulatory actions with respect to our or our competitors’ products or product candidates; 

•commencement or termination of collaborations for our development programs; 

•failure or discontinuation of any of our development programs; 

•regulatory or legal developments in the United States and other countries; 

•developments or disputes concerning patent applications, issued patents or other proprietary rights; 

•the recruitment or departure of key personnel; 

•the level of expenses related to any of our products, product candidates or development programs; 

•the results of our efforts to develop additional product candidates and products; 

•actual or anticipated changes in estimates as to financial results or development timelines; 

58

•announcement or expectation of additional financing efforts; 

•sales of our common stock by us, our insiders or other stockholders; 

•variations in our financial results or results of companies that are perceived to be similar to us; 

•changes in estimates, evaluations or recommendations by securities analysts, that cover our stock or the failure by one or more securities analysts to continue to cover our stock; 

•changes in the structure of healthcare payment systems; 

•market conditions in the pharmaceutical and biotechnology sectors; 

•general economic, political, industry and market conditions; and 

•the other factors described in this “Risk Factors” section. 

In the past, following periods of volatility in the market price of a company's securities, securities class-action litigation often has been instituted against that company. Such litigation, if instituted against us, could cause us to incur substantial costs to defend such claims and divert managements' attention and resources, which could seriously harm our business, financial condition, results of operations and prospects. 

We also cannot guarantee that an active trading market for our shares will be sustained. An inactive trading market for our common stock may impair our ability to raise capital to continue to fund our operations by selling shares and may impair our